Chinook Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Chinook Therapeutics, a biopharmaceutical company focused on kidney diseases, announced its participation in two upcoming virtual investor conferences. The H.C. Wainwright Bioconnect 2022 Conference features an on-demand fireside chat available from January 10 at 7:00 am EST, while the 40th Annual J.P. Morgan Healthcare Conference will include a presentation on January 12 at 1:30 pm EST. Additionally, Chinook will conduct 1x1 meetings. Archived webcasts of these events will be accessible for 30 days on the company's website.

SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming virtual investor conferences:

• H.C. Wainwright Bioconnect 2022 Conference – fireside chat will be available on-demand beginning Monday, January 10^th at 7:00 am EST
  
  
• 40^th Annual J.P. Morgan Healthcare Conference – presentation on Wednesday, January 12^th at 1:30 pm EST
  

Chinook will also participate in 1x1 meetings through H.C. Wainwright and J.P. Morgan.

To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit the Investors section of Chinook’s website. The archived webcasts will remain available for replay on Chinook’s website for 30 days.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

FAQ

What conferences will Chinook Therapeutics participate in January 2022?

Chinook Therapeutics will participate in the H.C. Wainwright Bioconnect 2022 Conference and the 40th Annual J.P. Morgan Healthcare Conference.

When is the Chinook Therapeutics fireside chat available?

The fireside chat for the H.C. Wainwright Bioconnect 2022 Conference will be available on-demand starting January 10, 2022, at 7:00 am EST.

What is the date of Chinook's presentation at the J.P. Morgan Healthcare Conference?

Chinook Therapeutics' presentation at the J.P. Morgan Healthcare Conference is scheduled for January 12, 2022, at 1:30 pm EST.

How long will the archived webcasts of Chinook's presentations be available?

The archived webcasts of Chinook Therapeutics' presentations will be available for replay on the company’s website for 30 days.

What is Chinook Therapeutics' lead program for kidney diseases?

Chinook Therapeutics' lead program is atrasentan, an endothelin receptor antagonist in phase 3 for IgA nephropathy and other proteinuric glomerular diseases.